MX2012007933A - Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. - Google Patents
Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.Info
- Publication number
- MX2012007933A MX2012007933A MX2012007933A MX2012007933A MX2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- topical transdermal
- transdermal dexmedetomidine
- dexmedetomidine compositions
- compositions
- Prior art date
Links
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title abstract 2
- 229960004253 dexmedetomidine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29344010P | 2010-01-08 | 2010-01-08 | |
| PCT/US2011/020462 WO2011085162A2 (en) | 2010-01-08 | 2011-01-07 | Topical transdermal dexmedetomidine compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007933A true MX2012007933A (es) | 2012-08-15 |
Family
ID=44306157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007933A MX2012007933A (es) | 2010-01-08 | 2011-01-07 | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130072532A1 (https=) |
| EP (1) | EP2521544A4 (https=) |
| JP (1) | JP2013516482A (https=) |
| CN (1) | CN102753169A (https=) |
| AU (1) | AU2011204315A1 (https=) |
| CA (1) | CA2786598A1 (https=) |
| MX (1) | MX2012007933A (https=) |
| NZ (2) | NZ703808A (https=) |
| RU (1) | RU2012133969A (https=) |
| WO (1) | WO2011085162A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013090278A2 (en) * | 2011-12-11 | 2013-06-20 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| CA2911472A1 (en) * | 2013-05-06 | 2014-11-13 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| US20150098982A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions |
| CA2924233C (en) | 2013-10-07 | 2018-10-23 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| KR101881791B1 (ko) * | 2013-10-07 | 2018-07-25 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
| CA2924236C (en) * | 2013-10-07 | 2020-01-07 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
| KR101948779B1 (ko) * | 2013-10-07 | 2019-05-21 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| MA41689A (fr) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
| BR112019006955A2 (pt) | 2016-10-31 | 2019-07-02 | Teikoku Pharma Usa Inc | métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina |
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| CN107929234B (zh) * | 2017-12-25 | 2021-07-23 | 温州医科大学附属第一医院 | 一种应用于烧伤创面修复的外用制剂膏体 |
| BR112020026672A2 (pt) | 2018-06-27 | 2021-03-30 | Bioxcel Therapeutics, Inc. | Formulações de filme contendo dexmedetomidina e métodos para produzi-las |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| EP3962478A1 (en) | 2019-05-01 | 2022-03-09 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| US20220211672A1 (en) | 2019-05-01 | 2022-07-07 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| BR112022000992A2 (pt) | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
| CN113577556A (zh) * | 2021-08-01 | 2021-11-02 | 武汉左点科技有限公司 | 一种用于阴道康复治疗的生物反馈电刺激方法及装置 |
| CN117582424A (zh) * | 2022-08-17 | 2024-02-23 | 宜昌人福药业有限责任公司 | 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217718A (en) * | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| GB9913677D0 (en) * | 1999-06-11 | 1999-08-11 | Imperial College | Formulation |
| AUPR184500A0 (en) * | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
| WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| GB0611241D0 (en) * | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
-
2011
- 2011-01-07 US US13/520,959 patent/US20130072532A1/en not_active Abandoned
- 2011-01-07 WO PCT/US2011/020462 patent/WO2011085162A2/en not_active Ceased
- 2011-01-07 NZ NZ703808A patent/NZ703808A/en not_active IP Right Cessation
- 2011-01-07 NZ NZ601195A patent/NZ601195A/en not_active IP Right Cessation
- 2011-01-07 EP EP11732180.2A patent/EP2521544A4/en not_active Withdrawn
- 2011-01-07 CN CN2011800088869A patent/CN102753169A/zh active Pending
- 2011-01-07 RU RU2012133969/15A patent/RU2012133969A/ru not_active Application Discontinuation
- 2011-01-07 AU AU2011204315A patent/AU2011204315A1/en not_active Abandoned
- 2011-01-07 JP JP2012548137A patent/JP2013516482A/ja active Pending
- 2011-01-07 MX MX2012007933A patent/MX2012007933A/es not_active Application Discontinuation
- 2011-01-07 CA CA2786598A patent/CA2786598A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011085162A2 (en) | 2011-07-14 |
| CA2786598A1 (en) | 2011-07-14 |
| WO2011085162A3 (en) | 2011-11-17 |
| CN102753169A (zh) | 2012-10-24 |
| EP2521544A2 (en) | 2012-11-14 |
| NZ703808A (en) | 2016-01-29 |
| NZ601195A (en) | 2015-02-27 |
| RU2012133969A (ru) | 2014-02-20 |
| EP2521544A4 (en) | 2013-08-21 |
| JP2013516482A (ja) | 2013-05-13 |
| AU2011204315A1 (en) | 2012-08-02 |
| US20130072532A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012007933A (es) | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| MX342951B (es) | Composiciones terapeuticamente activas y su metodo de uso. | |
| MX366318B (es) | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2015009592A (es) | Quinolina y quinazolina amidas como moduladores de canales de sodio. | |
| EP4647076A3 (en) | Therapeutically active compounds and their methods of use | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| PL2632452T3 (pl) | Związki i kompozycje stosowane w leczeniu nowotworów | |
| MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
| EP3054931A4 (en) | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions | |
| WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
| MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
| IL251543B (en) | Use of gel compounds in the production of medicine to prevent or treat skin diseases | |
| EP2897621A4 (en) | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| PH12013501163A1 (en) | Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
| EP3449917A3 (en) | Tapentadol for preventing chronification of pain | |
| DK2155179T3 (da) | Axomadol til smertebehandling arthrose | |
| MX366118B (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |